Esperion Therapeutics, Inc. — Revenue by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/39e3ebc9-96ab-4cb9-bd03-6a1044ab6eb4/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $403.1M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-016522 |
| FY 2024 | $332.3M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-011154 |
| FY 2023 | $116.3M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-007066 |
| FY 2022 | $75.5M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-004167 |
| FY 2021 | $78.4M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-003263 |
| FY 2020 | $227.5M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-002865 |
| FY 2019 | $148.4M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-026203 |
| FY 2018 | $0 | 2018-01-01 – 2018-12-31 | evidence 0001628280-21-002865 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Esperion Therapeutics, Inc. — all facts · Net Income · Operating Income